BACKGROUND: Human leukocyte antigen (HLA) antibodies are a possible cause of transfusion-related acute lung injury (TRALI), and fluorescent bead assays are often used for antibody detection. Serum is the manufacturer's recommended sample, but plasma may be easier to obtain for studies of HLA antibody prevalence and TRALI case investigations. STUDY DESIGN AND METHODS: Specimens were obtained from 44 multiparous females positive for the presence of HLA antibodies by lymphocytotoxicity testing at least 13 years prior and from 1000 contemporary blood donors. Screening tests were performed using a multiplex bead-based assay. In addition to comparing results obtained with paired plasma and serum samples, the effects of storage at 4 degrees C for 1 week and of multiple freeze-thaw cycles were evaluated. RESULTS: Of 42 evaluable subjects with HLA antibodies documented more than 13 years earlier, only 1 showed loss of detectable antibodies, with 39 (93%) positive in the screening assay for HLA Class I and 24 (57%) positive in the screening assay for HLA Class II antibodies. In 968 evaluable contemporary donors, 291 screened positive for the presence of HLA Class I and 206 for HLA Class II antibodies using a low assay cutoff. Screening test concordance using paired plasma and serum samples was high, particularly for subjects with higher-level antibodies. Refrigeration of samples for 1 week did not significantly affect assay results, while repeated freeze-thaw cycles caused a decrement in signal level. CONCLUSION: Serum and plasma samples gave concordant results in the majority of cases, particularly for specimens with higher-level antibodies. High-level HLA antibodies were present in most individuals for more than 13 years.
BACKGROUND:Human leukocyte antigen (HLA) antibodies are a possible cause of transfusion-related acute lung injury (TRALI), and fluorescent bead assays are often used for antibody detection. Serum is the manufacturer's recommended sample, but plasma may be easier to obtain for studies of HLA antibody prevalence and TRALI case investigations. STUDY DESIGN AND METHODS: Specimens were obtained from 44 multiparous females positive for the presence of HLA antibodies by lymphocytotoxicity testing at least 13 years prior and from 1000 contemporary blood donors. Screening tests were performed using a multiplex bead-based assay. In addition to comparing results obtained with paired plasma and serum samples, the effects of storage at 4 degrees C for 1 week and of multiple freeze-thaw cycles were evaluated. RESULTS: Of 42 evaluable subjects with HLA antibodies documented more than 13 years earlier, only 1 showed loss of detectable antibodies, with 39 (93%) positive in the screening assay for HLA Class I and 24 (57%) positive in the screening assay for HLA Class II antibodies. In 968 evaluable contemporary donors, 291 screened positive for the presence of HLA Class I and 206 for HLA Class II antibodies using a low assay cutoff. Screening test concordance using paired plasma and serum samples was high, particularly for subjects with higher-level antibodies. Refrigeration of samples for 1 week did not significantly affect assay results, while repeated freeze-thaw cycles caused a decrement in signal level. CONCLUSION: Serum and plasma samples gave concordant results in the majority of cases, particularly for specimens with higher-level antibodies. High-level HLA antibodies were present in most individuals for more than 13 years.
Authors: C C Silliman; N F Voelkel; J D Allard; D J Elzi; R M Tuder; J L Johnson; D R Ambruso Journal: J Clin Invest Date: 1998-04-01 Impact factor: 14.808
Authors: Christopher C Silliman; Lynn K Boshkov; Zahra Mehdizadehkashi; David J Elzi; William O Dickey; Linda Podlosky; Gwen Clarke; Daniel R Ambruso Journal: Blood Date: 2002-09-05 Impact factor: 22.113
Authors: Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Garth H Utter; Cathy Schechterly; Mila Lebedeva; Eva Operskalski; Naomi L Luban; Harvey Alter; Michael P Busch; Sherrill J Slichter; Philip J Norris Journal: Transfusion Date: 2013-06-30 Impact factor: 3.157
Authors: Danielle M Carrick; Bryce Johnson; Steven H Kleinman; Robert Vorhaben; Suzette C Chance; Jar-How Lee; John D Roback; Suchitra Pandey; Yu Sun; Michael P Busch; Philip J Norris Journal: Transfusion Date: 2010-11-18 Impact factor: 3.157
Authors: Robert O Endres; Steven H Kleinman; Danielle M Carrick; Whitney R Steele; David J Wright; Philip J Norris; Darrell Triulzi; Ram Kakaiya; Michael P Busch Journal: Transfusion Date: 2010-02-11 Impact factor: 3.157
Authors: Danielle M Carrick; Philip J Norris; Robert O Endres; Suchitra Pandey; Steven H Kleinman; David Wright; Yu Sun; Michael P Busch Journal: Transfusion Date: 2011-02-18 Impact factor: 3.157
Authors: Mark Seielstad; Grier P Page; Nathan Gaddis; Marion Lanteri; Tzong-Hae Lee; Ram Kakaiya; Lisa F Barcellos; Lindsey A Criswell; Darrell Triulzi; Philip J Norris; Michael P Busch Journal: Transfusion Date: 2017-11-22 Impact factor: 3.157
Authors: Manish J Gandhi; Danielle M Carrick; Sarah Jenkins; Steven De Goey; Nancy A Ploeger; Gregory A Wilson; Jar How Lee; Jeffrey L Winters; James R Stubbs; Pearl Toy; Philip J Norris Journal: Transfusion Date: 2013-01-10 Impact factor: 3.157
Authors: JoonHo Lee; Roberto Romero; Yi Xu; Jezid Miranda; Wonsuk Yoo; Piya Chaemsaithong; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Adi L Tarca; Steven J Korzeniewski; Sonia S Hassan; Nandor Gabor Than; Bo Hyun Yoon; Chong Jai Kim Journal: Am J Reprod Immunol Date: 2013-08 Impact factor: 3.886
Authors: Marc Ansari; Chakradhara Rao S Uppugunduri; Sylvie Ferrari-Lacraz; Henrique Bittencourt; Fabienne Gumy-Pause; Yves Chalandon; Jean-Marie Tiercy; Tal Schechter; Adam Gassas; John D Doyle; Lee Dupuis; Michel Duval; Maja Krajinovic; Jean Villard Journal: PLoS One Date: 2013-08-19 Impact factor: 3.240
Authors: Rachael P Jackman; Giovanna I Cruz; Joanne Nititham; Darrell J Triulzi; Lisa F Barcellos; Lindsey A Criswell; Philip J Norris; Michael P Busch Journal: Lupus Sci Med Date: 2018-09-25